The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics

References

• Moser J, Verdin P. Trial watch: burgeoning oncology pipeline raises questions about sustainability. Nat Rev Drug Discov. 2018 Oct 1;17(10):698–699.
   PubMed Web of Science ®Google Scholar
• Mullard A. 2018 FDA drug approvals. Nat Rev Drug Discov. 2019;18:85–89.
   PubMed Web of Science ®Google Scholar
• Tang J, Pearce L, O’Donnell-Tormey J, et al. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov. 2018 Oct 26;17(12):922.
   Web of Science ®Google Scholar
• Denis F, Basch E, Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321(3):306–307.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Beyond survival. Science. 2019;363:1166–1169.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121.
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2018;105:1091–1094.
   PubMed Web of Science ®Google Scholar
• Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018 Nov;19(11):1459–1467.
   PubMed Web of Science ®Google Scholar
• Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008;28:755–768.
   PubMed Web of Science ®Google Scholar
• Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630–634. .
   PubMed Web of Science ®Google Scholar
• Chabner BA. Clinical pharmacokinetics and drug monitoring. In: BA C, editor. pharmacologic principles of cancer treatment. Philadelphia: Saunders. 1982. p. p 100–8.
   Google Scholar
• Eksborg S, Ehrsson H. Drug level monitoring: cytostatics. J Chromatogr. 1985 May;10(340):31–72.
   Google Scholar
• Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin Pharmacokinet. 1987;13(4):205–227.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet. 1989 Jun;16(6):327–336.
   PubMed Web of Science ®Google Scholar
• Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem. 1993 Nov;39(11 Pt 2):2419–2430.
   PubMedGoogle Scholar
• Bardin C, Veal G, Paci A, et al. Therapeutic drug monitoring in cancer–are we missing a trick? Eur J Cancer. 2014;50(12):2005–2009.
   PubMed Web of Science ®Google Scholar
• Paci A, Veal G, Bardin C, et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Eur J Cancer. 2014;50(12):2010–2019.
   PubMed Web of Science ®Google Scholar
• Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies. Eur J Cancer. 2014;50(12):2020–2036.
   PubMed Web of Science ®Google Scholar
• Yu H, Steeghs N, Nijenhuis CM, et al. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014 Apr;53(4):305–325.
   PubMed Web of Science ®Google Scholar
• Verheijen RB, Yu H, Schellens JHM, et al. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017 Nov;102(5):765–776.
   PubMed Web of Science ®Google Scholar
• Groenland SL, van Nuland M, Verheijen RB, et al. Therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Clin Pharmacokinet. 2019 Mar;58(3):299–308.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 2014 May;11(5):272–281. .
   PubMed Web of Science ®Google Scholar
• Moreau-Bachelard C, Coquan E, Le Tourneau C. Imputability of adverse events to anticancer drugs. N Engl J Med. 2019;380(19):1873–1874.
   PubMed Web of Science ®Google Scholar
• Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55–61.
   PubMed Web of Science ®Google Scholar
• Bhagwatwar HP, Phadungpojna S, Chow DS, et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37(5):401–408.
   PubMed Web of Science ®Google Scholar
• US S, Ehrsam M, Schneider A, et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22(3):241–244.
   PubMed Web of Science ®Google Scholar
• Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113–123.
   PubMed Web of Science ®Google Scholar
• Grochow LB. Parenteral busulfan: is therapeutic monitoring still warranted? Biol Blood Marrow Transplant. 2002;8(9):465–467.
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Lalmohamed A, van Reij EM, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov;3(11):e526–e536. .
   PubMed Web of Science ®Google Scholar
• Bartelink IH, Lalmohamed A, Long-Boyle JR, et al. Busulfan after HSCT in children and young adults - authors’ reply. Lancet Haematol. 2017;4(3):e103–e104.
   PubMedGoogle Scholar
• McCune JS, Quinones CM, Ritchie J, et al. Harmonization of busulfan plasma exposure unit (BPEU): a community-initiated consensus statement. Biol Blood Marrow Transplant. 2019 May 25. Epub ahead of print.
   Web of Science ®Google Scholar
• Thyss A, Milano G, Renée N, et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol. 1986;16(1):64–66.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Allegra C, et al. Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther. 2019;105(3):598–613. .
   PubMed Web of Science ®Google Scholar
• Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4(9):2039–2045.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099–2105. Erratum in: J Clin Oncol. 2013;31(28):3612. .
   PubMed Web of Science ®Google Scholar
• Santé HA. Recherche de déficit en dihydropyrimidine deshydrogenase en vue de prévenir certaines toxicités sévères survenant sous traitement comportant des fluoropyrimidines. 2019 Apr [cited 2019 Jun 13]. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-12/recherche_dun_deficit_en_dihydropyrimidine_deshydrogenase_visant_a_prevenir_certaines_toxicites_severes_associees_aux_traite.pdf
   Google Scholar
• Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17(3):296–302.
   PubMed Web of Science ®Google Scholar
• Levêque D, Becker G, Toussaint E, et al. Clinical pharmacokinetics of methotrexate in oncology. Int J Pharmacokinet. 2017;2:137–147.
   Google Scholar
• Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231–e239.
   PubMed Web of Science ®Google Scholar
• Dupuis C, Mercier C, Yang C, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 2008;19:267–273.
   PubMed Web of Science ®Google Scholar
• Foster JH, Thompson PA, Bernhardt MB, et al. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019;83(2):349–360.
   PubMed Web of Science ®Google Scholar
• Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia. 2000;14:221–225.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957.
   PubMed Web of Science ®Google Scholar